Park Ha Biological Technology is trading 6.1% down at $0.35 as low liquidity and persistent weak demand continue to weigh on the thinly traded small-cap.
- The move comes despite a lack of fresh company-specific headlines, earnings, or regulatory filings, following a series of recent declines for the stock.
- Park Ha’s slide contrasts with recent strength in the broader biotech sector, suggesting the volatility is driven by cautious risk sentiment toward speculative micro-cap names.